Global Markets Direct: Market Research Reports

Global Markets Direct is a cutting-edge provider of market research and business consultancies for a wide range of customers worldwide.

A team of analytics is capable to produce all sorts of market information and carry out extensive industry research using unique data and reliable sources to let customers know who they are at the market. Global Markets Direct has profound analytical experience in researching the industries and preparing customized reports across many specific fields.

The company is distinguished by its high-quality consulting products and close inspection of the issues under study. Diligent efforts of the experts make every piece of business information an exclusive source of feasible solutions and valuable advice.

With a commitment to serve every client need, Global Markets Direct collects and interprets the materials for the analysis, uses methods of primary and secondary research and develops one of a kind data packages for global clients. They are able to cover the tones of industry-related information to assist customers in taking the right business decisions and developing their strategic plans.

Under the supervision of skillful managers and experts, business analysts produce reports that include:

Product portfolio
Potentially strong market reviews
Competitive analytics
Prospect partners
Mergers and acquisitions project data
Latest trends across a particular industry area
Research and development strategies
The analysis of new customers
A set of remedial measures for projects

They will search for new partners and highlight the current business issues plus develop new strategies and tactical steps to help you take the lead in the industry where you operate.

Publications found: 5,853

Sort by:

Cells Expressing Claudin 18 (CLDN18) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Claudin 18 (CLDN18) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Cells Expressing Claudin 18 (CLDN18) Drugs in Develo...

May 2022 82 pages

Cells Expressing Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type...

May 2022 36 pages

Cells Expressing Delta Like Protein 3 (Drosophila Delta Homolog 3 or DLL3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Delta Like Protein 3 (Drosophila Delta Homolog 3 or DLL3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Cells Expressi...

May 2022 40 pages

Cells Expressing Folate Receptor (FOLR) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Folate Receptor (FOLR) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Cells Expressing Folate Receptor (FOLR) Drugs in...

May 2022 35 pages

Cells Expressing Glypican 3 (Heparan Sulphate Proteoglycan or Intestinal Protein OCI 5 or GTR2 2 or MXR7 or GPC3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Glypican 3 (Heparan Sulphate Proteoglycan or Intestinal Protein OCI 5 or GTR2 2 or MXR7 or GPC3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type...

May 2022 84 pages

Cells Expressing GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Cells Ex...

May 2022 43 pages

Cells Expressing Hepatocyte Growth Factor Receptor (Proto Oncogene c Met or Tyrosine Protein Kinase Met or HGF-SF Receptor or Scatter Factor Receptor or MET or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Hepatocyte Growth Factor Receptor (Proto Oncogene c Met or Tyrosine Protein Kinase Met or HGF-SF Receptor or Scatter Factor Receptor or MET or EC 2.7.10.1) Drugs in Development by The...

May 2022 41 pages

Cells Expressing Human Papillomavirus Protein E7 (E7) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Human Papillomavirus Protein E7 (E7) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Cells Expressing Human Papillomavir...

May 2022 37 pages

Cells Expressing Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Ce...

May 2022 35 pages

Cells Expressing Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY C...

May 2022 40 pages

Cells Expressing Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY C...

May 2022 36 pages

Cells Expressing Interleukin 13 Receptor Subunit Alpha 2 (Interleukin 13 Binding Protein or CD213a2 or IL13RA2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Interleukin 13 Receptor Subunit Alpha 2 (Interleukin 13 Binding Protein or CD213a2 or IL13RA2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type a...

May 2022 48 pages

Cells Expressing Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMA...

May 2022 43 pages

Cells Expressing Interleukin 3 Receptor Subunit Alpha (CD123 or IL3RA) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Interleukin 3 Receptor Subunit Alpha (CD123 or IL3RA) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Cells Expressing I...

May 2022 77 pages

Cells Expressing Latent Membrane Protein 1 (Protein p63 or LMP1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Latent Membrane Protein 1 (Protein p63 or LMP1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Cells Expressing Latent...

May 2022 38 pages

Cells Expressing Latent Membrane Protein 2 (Terminal Protein or LMP2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Latent Membrane Protein 2 (Terminal Protein or LMP2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Cells Expressing La...

May 2022 37 pages

Cells Expressing Leukocyte Antigen CD37 (Tetraspanin 26 or CD37) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Leukocyte Antigen CD37 (Tetraspanin 26 or CD37) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Cells Expressing Leukocy...

May 2022 46 pages

Cells Expressing Mast-Stem Cell Growth Factor Receptor Kit (Proto Oncogene c Kit or Tyrosine Protein Kinase Kit or v Kit Hardy Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog or Piebald Trait Protein or p145 c Kit or CD117 or KIT or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Mast-Stem Cell Growth Factor Receptor Kit (Proto Oncogene c Kit or Tyrosine Protein Kinase Kit or v Kit Hardy Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog or Piebald Trait Protei...

May 2022 39 pages

Cells Expressing Melanoma Antigen Preferentially Expressed In Tumors (Cancer-Testis Antigen 130 or Opa Interacting Protein 4 or OIP4 or Preferentially Expressed Antigen Of Melanoma or PRAME) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Melanoma Antigen Preferentially Expressed In Tumors (Cancer-Testis Antigen 130 or Opa Interacting Protein 4 or OIP4 or Preferentially Expressed Antigen Of Melanoma or PRAME) Drugs in...

May 2022 46 pages

Cells Expressing Melanoma Antigen Recognized By T Cells 1 (Protein Melan A or Antigen SK29 AA or Antigen LB39 AA or MART1 or MLANA) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Melanoma Antigen Recognized By T Cells 1 (Protein Melan A or Antigen SK29 AA or Antigen LB39 AA or MART1 or MLANA) Drugs in Development by Therapy Areas and Indications, Stages, MoA,...

May 2022 36 pages

Cells Expressing Melanoma Associated Antigen 3 (Antigen MZ2D or Cancer-Testis Antigen 1.3 or MAGE3 Antigen or MAGEA3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Melanoma Associated Antigen 3 (Antigen MZ2D or Cancer-Testis Antigen 1.3 or MAGE3 Antigen or MAGEA3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule...

May 2022 41 pages

Cells Expressing Melanoma Associated Antigen 4 (Cancer-Testis Antigen 1.4 or MAGE 4 Antigen or MAGE 41 Antigen or MAGE X2 Antigen or MAGEA4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Melanoma Associated Antigen 4 (Cancer-Testis Antigen 1.4 or MAGE 4 Antigen or MAGE 41 Antigen or MAGE X2 Antigen or MAGEA4) Drugs in Development by Therapy Areas and Indications, Stag...

May 2022 49 pages

Cells Expressing Mesothelin (CAK1 Antigen or Pre Pro Megakaryocyte Potentiating Factor or MSLN) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Mesothelin (CAK1 Antigen or Pre Pro Megakaryocyte Potentiating Factor or MSLN) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players S...

May 2022 111 pages

Cells Expressing Mucin 16 (Ovarian Cancer Related Tumor Marker CA125 or Ovarian Carcinoma Antigen CA125 or MUC16) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Mucin 16 (Ovarian Cancer Related Tumor Marker CA125 or Ovarian Carcinoma Antigen CA125 or MUC16) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type...

May 2022 40 pages

Cells Expressing Myeloid Cell Surface Antigen CD33 (Sialic Acid Binding Ig Like Lectin 3 or gp67 or CD33) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Myeloid Cell Surface Antigen CD33 (Sialic Acid Binding Ig Like Lectin 3 or gp67 or CD33) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key...

May 2022 82 pages

Cells Expressing Neural Cell Adhesion Molecule 1 (Antigen Recognized By Monoclonal Antibody 5.1H11 or CD56 or NCAM1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Neural Cell Adhesion Molecule 1 (Antigen Recognized By Monoclonal Antibody 5.1H11 or CD56 or NCAM1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule T...

May 2022 37 pages

Cells Expressing Neural Cell Adhesion Molecule L1 (CD171 or L1CAM) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Neural Cell Adhesion Molecule L1 (CD171 or L1CAM) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Cells Expressing Neura...

May 2022 35 pages

Cells Expressing Phosphatidylserine Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Phosphatidylserine Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Cells Expressing Phosphatidylserine Drugs in Developm...

May 2022 37 pages

Cells Expressing Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Cells...

May 2022 65 pages

Cells Expressing Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Cells Expressing...

May 2022 47 pages

Cells Expressing Prominin 1 (Antigen AC133 or Prominin Like Protein 1 or CD133 or PROM1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Prominin 1 (Antigen AC133 or Prominin Like Protein 1 or CD133 or PROM1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY...

May 2022 41 pages

Cells Expressing Prostate Stem Cell Antigen (PSCA) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Prostate Stem Cell Antigen (PSCA) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Cells Expressing Prostate Stem Cell An...

May 2022 40 pages

Cells Expressing Somatostatin Receptor (SSTR) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Somatostatin Receptor (SSTR) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Cells Expressing Somatostatin Receptor (SST...

May 2022 37 pages

Cells Expressing Somatostatin Receptor Type 2 (SRIF1 or SSTR2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Somatostatin Receptor Type 2 (SRIF1 or SSTR2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Cells Expressing Somatosta...

May 2022 38 pages

Cells Expressing Syndecan 1 (CD138 or SDC1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Syndecan 1 (CD138 or SDC1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Cells Expressing Syndecan 1 (CD138 or SDC1) D...

May 2022 41 pages

Cells Expressing T Cell Antigen CD7 (GP40 or T Cell Leukemia Antigen or T Cell Surface Antigen Leu 9 or TP41 or CD7) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing T Cell Antigen CD7 (GP40 or T Cell Leukemia Antigen or T Cell Surface Antigen Leu 9 or TP41 or CD7) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule T...

May 2022 52 pages

Cells Expressing T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4-Leu 3 or CD4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4-Leu 3 or CD4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY...

May 2022 35 pages

Cells Expressing T Cell Surface Glycoprotein CD5 (Lymphocyte Antigen T1-Leu 1 or CD5) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing T Cell Surface Glycoprotein CD5 (Lymphocyte Antigen T1-Leu 1 or CD5) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Cel...

May 2022 41 pages

Cells Expressing Tumor Associated Glycoprotein 72 (TAG72) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Tumor Associated Glycoprotein 72 (TAG72) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Cells Expressing Tumor Associat...

May 2022 37 pages

Cells Expressing Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMAR...

May 2022 37 pages

Cells Expressing Wilms Tumor Protein (WT33 or WT1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cells Expressing Wilms Tumor Protein (WT33 or WT1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players SUMMARY Cells Expressing Wilms Tumor Protein (...

May 2022 57 pages

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Playe...

May 2022 66 pages

Cellulitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Cellulitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Cellulitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides a...

May 2022 35 pages

Cerebral Edema Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Cerebral Edema Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Cerebral Edema Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players pr...

May 2022 39 pages

Cerebral (Fatal) Malaria Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Cerebral (Fatal) Malaria Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Cerebral (Fatal) Malaria Drugs in Development by Stages, Target, MoA, RoA, Molecule Typ...

May 2022 35 pages

Cerebral Infarction (Brain Infarction) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Cerebral Infarction (Brain Infarction) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Cerebral Infarction (Brain Infarction) Drugs in Development by Stages, Ta...

May 2022 45 pages

Charcot-Marie-Tooth Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Charcot-Marie-Tooth Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Charcot-Marie-Tooth Disease Drugs in Development by Stages, Target, MoA, RoA, Molecu...

May 2022 70 pages

Charcot-Marie-Tooth Disease Type I A Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Charcot-Marie-Tooth Disease Type I A Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Charcot-Marie-Tooth Disease Type I A Drugs in Development by Stages, Target...

May 2022 45 pages

Charcot-Marie-Tooth Disease Type II Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,000.00

Charcot-Marie-Tooth Disease Type II Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Charcot-Marie-Tooth Disease Type II Drugs in Development by Stages, Target,...

May 2022 43 pages

Chemotherapy Effects Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

US$ 2,500.00

Chemotherapy Effects Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players SUMMARY Chemotherapy Effects Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Ke...

May 2022 239 pages